These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38636292)

  • 1. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis.
    Dannehl D; Jakob D; Mergel F; Estler A; Engler T; Volmer L; Frevert ML; Matovina S; Englisch A; Tegeler CM; Rohner A; Seller A; Hahn M; Pfister K; Fink A; Popp I; Lorenz S; Tabatabai G; Juhasz-Böss I; Janni W; Brucker S; Taran FA; Hartkopf A; Schäffler H
    ESMO Open; 2024 May; 9(5):102995. PubMed ID: 38636292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.
    Poumeaud F; Morisseau M; Cabel L; Gonçalves A; Rivier C; Trédan O; Volant E; Frenel JS; Ladoire S; Jacot W; Jamelot M; Foka Tichoue H; Patsouris A; Teixeira L; Bidard FC; Loirat D; Brunet M; Levy C; Bailleux C; Cabarrou B; Deleuze A; Uwer L; Deluche E; Grellety T; Franchet C; Fiteni F; Bischoff H; Vion R; Pagliuca M; Verret B; Bécourt S; Reverdy T; de Nonneville A; Dalenc F
    Br J Cancer; 2024 Sep; 131(4):702-708. PubMed ID: 38918555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
    Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
    ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis.
    Pedersini R; Buffoni M; Petrelli F; Ghidini A; di Mauro P; Amoroso V; Parati MC; Laini L; Cosentini D; Schivardi G; Ippolito G; Berruti A; Laganà M
    Clin Breast Cancer; 2024 Jul; 24(5):411-420. PubMed ID: 38734491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.
    Vaz Batista M; Pérez-García JM; Cortez P; Garrigós L; Fernández-Abad M; Gion M; Martínez-Bueno A; Saavedra C; Teruel I; Fernandez-Ortega A; Servitja S; Ruiz-Borrego M; de la Haba-Rodríguez J; Martrat G; Pérez-Escuredo J; Alcalá-López D; Sampayo-Cordero M; Braga S; Cortés J; Llombart-Cussac A
    ESMO Open; 2024 Sep; 9(9):103699. PubMed ID: 39255534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
    Adams E; Wildiers H; Neven P; Punie K
    ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast Centers.
    Schäffler H; Jakob D; Huesmann S; Pfister K; Veselinovic K; Schochter F; Leinert E; Fink V; Rack B; Englisch A; Volmer LL; Engler T; Frevert ML; Juhasz-Böss I; Brucker S; Heublein S; Janni W; Taran FA; Hartkopf A; Dannehl D
    Geburtshilfe Frauenheilkd; 2024 Sep; 84(9):855-865. PubMed ID: 39229630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance.
    Chen M; Huang R; Chen R; Pan F; Shen X; Li H; Rong Q; An X; Xue C; Shi Y
    Oncologist; 2024 Aug; 29(8):e957-e966. PubMed ID: 38574190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.
    Isogai A; Nozawa K; Nakakami A; Komaki R; Ozaki Y; Endo Y; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H
    Breast Cancer Res Treat; 2024 Sep; 207(2):253-261. PubMed ID: 38797792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis.
    Michelon I; Vilbert M; Marinho AD; Castro CER; Dacoregio MI; Stecca C; Soares LR; Batista MV; Braga S; Saeed A; Cavalcante L
    ESMO Open; 2024 Feb; 9(2):102233. PubMed ID: 38320430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.
    Kabraji S; Ni J; Sammons S; Li T; Van Swearingen AED; Wang Y; Pereslete A; Hsu L; DiPiro PJ; Lascola C; Moore H; Hughes M; Raghavendra AS; Gule-Monroe M; Murthy RK; Winer EP; Anders CK; Zhao JJ; Lin NU
    Clin Cancer Res; 2023 Jan; 29(1):174-182. PubMed ID: 36074155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
    Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
    Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
    Nakayama T; Niikura N; Yamanaka T; Yamamoto M; Matsuura K; Inoue K; Takahara S; Nomura H; Kita S; Yamaguchi M; Aruga T; Shibata N; Shimomura A; Ozaki Y; Sakai S; Takiguchi D; Takata T; Bastanfard A; Shiosakai K; Tsurutani J
    Breast Cancer; 2024 Nov; 31(6):1167-1175. PubMed ID: 39133378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
    Yamashita T; Sohn JH; Tokunaga E; Niikura N; Park YH; Lee KS; Chae YS; Xu B; Wang X; Im SA; Li W; Lu YS; Aguilar CO; Nishijima S; Nishiyama Y; Sugihara M; Modi S; Tsurutani J
    Breast Cancer; 2024 Sep; 31(5):858-868. PubMed ID: 38884900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.
    Lee J; Kida K; Koh J; Liu H; Manyam GC; Gi YJ; Rampa DR; Multani AS; Wang J; Jayachandran G; Lee DW; Reuben JM; Sahin A; Huo L; Tripathy D; Im SA; Ueno NT
    J Exp Clin Cancer Res; 2024 Aug; 43(1):236. PubMed ID: 39164784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression.
    Rogawski D; Cao T; Ma Q; Roy-O'Reilly M; Yao L; Xu N; Nagpal S
    J Neurooncol; 2024 Oct; 170(1):209-217. PubMed ID: 39073687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
    McGuinness JE; Kalinsky K
    Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
    Guarneri V; Passos Coelho JL; Duhoux FP; Egle D; García-Sáenz JÁ; Penault-Llorca F; Selander K; Wildiers H; Zaman K; Laeis P; Lucerna M; Pierga JY
    Future Oncol; 2024; 20(18):1237-1250. PubMed ID: 38592002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
    De Moura A; Loirat D; Vaillant S; Korbi S; Kiavue N; Bello Roufai D; Escalup L; Desmaris R; Vaflard P; Cottu P; Pierga JY; Bidard FC; Cabel L; Acramel A
    Breast Cancer; 2024 Jul; 31(4):572-580. PubMed ID: 38600429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.